Lpath Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has reported interim results in its Phase 2a trial investigating the drug Asonep as a treatment for metastatic renal cell carcinoma.
6335 Ferris Sq. Ste., A
San Diego, CA 92121
All contents herein copyright San Diego Source | The Daily Transcript ® 1994-2014